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     INTRODUCTION 
  The neglected tropical diseases (NTDs) are a group of con-
ditions causing significant morbidity and mortality worldwide 
but which until recently received only minimal attention from 
most of the world, largely because they affect the poorest, 
most vulnerable and most disenfranchised members of soci-
ety.  1   Afflicting more than one billion persons, one-sixth of the 
world’s population, these diseases cause severe disfigurement, 
disability, and blindness. The NTDs are among the leading per-
petuators of poverty because they significantly diminish eco-
nomic productivity in affected adults and because they impair 
the intellectual and physical development of the next genera-
tion in disease-endemic areas, setting already vulnerable chil-
dren on a path to lifelong disability that reinforces a cycle of 
poverty.  1  
  Among the 15 most prominent NTDs,  2   seven have simi-
lar strategies to address their control; namely, single doses of 
effective treatment, termed preventive chemotherapy (PCT), 
given once or twice a year to broad segments of the popu-
lation in disease-endemic areas through mass drug adminis-
tration (MDA). These seven diseases are lymphatic filariasis 
(LF), onchocerciasis, schistosomisis, trachoma, and three soil-
transmitted helminth (STH) infections (ascariasis, hookworm, 
and trichuriasis).  3  The treatment and diagnostic tools currently 
available for this group of diseases are sufficiently effective for 
these NTDs to be targeted either for elimination or for reduc-
tion to such low levels that they no longer constitute a signifi-
cant public health problem. 
  Most of the drugs used in these single-dose, once- or twice 
a year treatment regimens are donated through large public-
private partnerships that bring together public health imple-
menters, public-sector and private-sector donors, and the major 
pharmaceutical firms producing these drugs (GlaxoSmithKline, 
Johnson & Johnson, Merck and Co., Inc., Merck-Serono, and 
Pfizer).  4   
  Historically, many Ministries of Health in disease-endemic 
countries have supported the control of NTDs through inde-
pendent, often parallel, programs, with each maintaining its 
own planning, funding, drug supply chain, MDA campaign, 
monitoring, and evaluation. If funding were available for 
one program, that program might have been able to imple-
ment preventive chemotherapy while a sister program could 
not. However, because there is considerable overlap of these 
diseases in persons and communities, controlling one of the 
NTDs and not others that could be managed through a similar 
strategy is inefficient at best. Furthermore, research has pro-
vided sufficient evidence to suggest that co-implementation of 
the integrated PCT programs is safe for persons and commu-
nities in all but a few specific settings (e.g.,   Loa loa   co-ende-
micity with onchocerciasis or LF).  3  
  Because of the similarity of their strategic approaches, the 
epidemiologic overlap among affected populations and the 
availability of donated drugs, these NTD control programs 
seemed ideally suited for implementation that could be car-
ried out not in parallel, independent fashion, but, rather inte-
grated in a way where coordinated treatment interventions 
for multiple diseases could reduce the duplication of effort 
expended in treating the diseases separately. Such integra-
tion, here considered in the broadest sense as coordination of 
program activities among different disease-specific programs 
and as linkages of these activities with other elements of the 
health care system, should lead to efficiencies of delivery, 
enhanced effectiveness, increased health benefits, and better 
use of limited resources that could permit more at-risk per-
sons to be reached.  5   The World Health Organization (WHO) 
has endorsed such co-implementation of programs as the inte-
grated approach to preventive chemotherapy. 
  Early pilot studies of NTD program integration generally 
showed that despite many practical challenges, such integra-
tion was likely to be feasible and to result in at least some of 
the anticipated efficiencies and cost savings.  6–  8   Although it was 
clear from these pilot studies that certain elements of program 
implementation were more amenable to successful integration 
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than others, it was not clear either how successful the scaling 
up of these integration efforts from pilot studies to national-
scale programs could be or just which combinations of activi-
ties were most effectively linked. 
  The opportunity to document the feasibility of integrated 
approaches to NTD control at full national-scale presented 
itself when the U.S. Congress in 2006 authorized funds for “the 
integrated control of neglected tropical diseases.”  9  This  autho-
rization led to the establishment of NTD Control Program 
of the United States Agency for International Development 
(USAID) that envisioned, over a five-year period, facilitating 
integrated NTD programs in 15 countries. The present report 
documents the considerable achievements of the first three 
years of this NTD Control Program towards the development 
and growth of national integrated NTD programs and in their 
expansion to full national scale. 
   METHODS 
    The NTD Control Program.     Goals  and  approach.    The 
USAID NTD Control Program initiated activities in September 
2006. Its defined target was to enable the provision of 160 
million preventive chemotherapy treatments to 40 million 
people in 15 countries through integrated NTD programs 
over five years. The stated aims of the program have been 
1) to support and empower national governments to develop 
integrated NTD control programs embedded, where possible, 
within existing service delivery platforms and to lead these 
programs in scaling-up activities to full national levels; 2) to 
provide technical assistance for planning, budgeting, reporting, 
and complying with international standards and guidelines 
(  Table 1  ) to improve program integration; 3) to promote 
cost-efficiency, improved integration strategies, and effective 
advocacy; and 4) to assure national ownership, continued 
commitment, and resource mobilization for sustained support 
for NTD control. 
      The  prime  contractor,  RTI  International,  has  provided 
grants and coordination for a team of non-governmental 
organizations (NGOs) and implementing partners to support 
integrated NTD control programs organized and led by the 
governments of selected countries. The support from the U.S. 
Government was intended to build on existing commitments 
by governments and other donors and fill financial and techni-
cal gaps that were preventing national programs from reach-
ing full national scale. The program was mandated to track 
and report on the additional numbers of persons reached and 
treatments provided through support of the NTD Control 
Program (recognizing that in some countries other support 
also exists for NTD control). 
    Participating  countries  and  NGOs.    The  countries  currently 
involved in the USAID-supported, RTI-coordinated NTD 
Control Program are identified in   Table 2  , along with the lead 
NGO responsible in each country for interfacing between the 
national Ministry of Health and RTI. Those five countries that 
had earlier pilot programs, initiated with support from the 
Bill and Melinda Gates Foundation  10   and aimed at integrating 
disease-specific NTD control activities, are referred to as 
the fast-track countries because they could begin scaling 
up activities immediately; additional countries have been 
brought into the program progressively. By the end of year 
3, 12 countries were included in the program, of which 7 were 
actively engaged in yearly MDAs. It is from these first seven 
implementing countries that the quantitative measures of the 
NTD Control Program’s programmatic achievement during 
its first 3 years (reported below) are derived. 
        Drug distribution.   All drugs were distributed by the national 
Ministries of Health whose national NTD control programs 
determined how best to implement their MDAs (  Table 2  ). 
The drugs were used according to WHO recommendations 
(  Table 1  ). When disease co-endemicity required the use 
of multiple drugs (including combinations of albendazole, 
diethylcarbamazine [DEC], ivermectin, mebendazole or 
praziquantel), these were generally given at the same time, 
although sometimes the praziquantel treatment was delayed 
for at least a week after the other drugs were administered. 
When azithromycin was required, its administration was 
always at least a week separated from those of the other drugs, 
as currently recommended. 
  Albendazole for treatment of LF was donated by 
GlaxoSmithKline  11  ; when used to treat STH in areas where 
LF is not endemic, albendazole was obtained from pre-qual-
ified generic manufacturers. Azithromycin (Zithromax) was 
donated by Pfizer.  12  Diethylcarbamazine was obtained through 
WHO from pre-qualified generic manufacturers. Ivermectin 
(Mectizan) was donated by Merck & Co., Inc.  13   Mebendazole 
was donated by Johnson & Johnson  4   to treat persons with 
STH in countries where its Children Without Worms program 
operates. Tetracycline eye ointment was obtained from pre-
qualified generic manufacturers. 
   Technical  assessments.     Mapping.    Because  knowledge 
of the distribution of each NTD in a country is absolutely 
essential for developing any implementation (or integrated-
implementation) plan, disease-specific mapping was carried 
out according to guidelines recommended by WHO and its 
partners (  Table 3  ). Although some of these guidelines are still 
evolving, for all program assessments, the most up-to-date 
recommendations were followed. 
       Program  metrics.     To document progress toward achieving 
the program’s targets of 40 million additional persons treated 
with 160 million treatments over 5 years, the following 
indicators were used to track country-specific program progress: 
1) number of countries supported by the NTD Control Program; 
2) number of additional districts (implementation units) 
mapped for each endemic disease; 3) number of people treated 
(i.e., receiving at least one drug or drug package) and recorded in 
MDA registers for each round of PCT; 4) number of additional 
(i.e., made possible through support from the NTD Control 
Program) treatments provided (i.e. number of times a single 
drug dose is administered) and recorded in MDA registers for 
each round of PCT; 5) number of additional implementation 
units reached and reported by national programs for each round 
of PCT; 6) programmatic coverage: % targeted population 
reached with appropriate PCT treatment each round of PCT and 
calculated from register reports as the number treated divided 
by treatment-eligible population targeted in the implementation 
unit (as defined by census reports); 7) geographic coverage: % 
of endemic districts covered by PCT programs; and 8) number 
of persons trained for integrated NTD control through support 
from the NTD Control Program. 
    Program  expenditures.     Funding levels for each of the 
program’s first three years approximated $13.5 million per 
year, with the mandate that at least 80% of total annual 
resources be allocated to country program implementation 
and that overall management costs by RTI (whose role was to 7 INTEGRATED IMPLEMENTATION OF NTD PROGRAMS
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ensure financial accountability of all funds expended and to 
provide requested technical assistance to national programs) 
be no more than 20%. Of the 80% allocated for country 
implementation activities, approximately 20% was earmarked 
for procurement of essential drugs not available through 
donation programs (i.e., PZQ for schistosomiasis, DEC for LF, 
and albendazole for childhood de-worming in areas where LF 
is not co-endemic). 
    RESULTS 
    Mapping the geographic distribution of the targeted NTDs.  
  Because knowing the distribution of the targeted NTDs is 
essential for developing an implementation strategy, the first 
efforts of the NTD Control Program in the participating 
countries focused on cataloging the disease-distribution 
information available and then supporting on-the-ground 
efforts to map the distribution of infection where sufficient 
information was not available. 
    Table 4   aggregates the data from all of the districts in the 
first seven implementing countries (identified in   Table 2  ) and 
indicates the total number of districts that had been mapped 
for each of the NTDs prior to the initiation of the NTD 
Control Program. It is clear that mapping was already well 
advanced for LF. For the other diseases, there was still a great 
need for additional information on the distribution of these 
infections. 
              Table 4   also shows the progress made by the end of the first 
three years of support to the participating countries through 
the NTD Control Program. For each of the targeted diseases, 
mapping activities progressively defined the extent of the tar-
geted diseases, and as a result of these efforts and those of 
other partners, only a small number of districts in these coun-
tries remained to be mapped for these NTDs at the end of 
year 3 (now targeted for subsequent years’ activities). 
      Persons treated and number of treatments delivered in 
years 1–3.     Although programs targeting the individual NTDs 
were active in many countries prior to the inception of the 
NTD Control Program, few countries approached these 
diseases with an integrated control strategy. As seen in 
  Figure 1A  , after the fast track countries, with earlier support 
for pilot-scale integration studies by the Bill and Melinda 
Gates Foundation,  10   began to receive support for integrated 
programs from the NTD Control Program, there was a 
progressive increase in numbers of persons reached each 
year, beginning with 16 million additional individuals in the 
first year and reaching 27 and 55 million additional persons in 
each of the second and third years. (These numbers identify 
only those persons whose treatment was made possible 
by support to national programs from the NTD Control 
 Table 2 
    Principal drug distribution strategy in disease-endemic districts  *     
    *     NTD = neglected tropical disease; LF = lymphatic filariasis; STH = soil-transmitted helminths; NGO = nongovernment organizations; NA = not applicable.   
    †     General features of different distribution strategies described by national programs. Community distribution = in the market, mosque, or other busy places, common in urban settings; School-
based distribution = in schools, targeting only children in schools; Household distribution = house-to-house, where the drug distributor brings the drugs to persons in their homes; Health center 
distribution = at a health center, where persons come to the health center to receive the drugs; Mobile distribution = through distributors traveling by vehicle to find households in remote areas, 
particularly in nomadic zones; Distribution posts = at locations such as schools, churches, or along the roadside, used in both rural and urban settings.   
NTD control 
program Country
Principal drug distribution strategy in disease-endemic districts  † 
Lead NGO LF Onchocerciasis Schistosomiasis STH Trachoma
“Fast-track” 
countries
Burkina Faso Community 
Household 
Health center 
Mobile
Community 
Household 
Health center 
Mobile
Community 
School-based 
Household 
Health center 
Mobile
Community 
Household 
Health center 
Mobile
Community 
Household 
Health center 
Mobile
Schistosomiasis 
Control 
Initiative
Ghana Community Community School-based Community Transmission 
of blinding 
trachoma 
interrupted
World Vision
Mali Community 
School-based 
Household 
Mobile
School-based 
Household
School-based 
Household 
Mobile
Community 
School-based 
Household 
Mobile
School-based 
Household 
Mobile
Helen Keller 
International
Niger School-based 
Household
NA School-based 
Household
School-based 
Household
School-based 
Household
Schistosomiasis 
Control 
Initiative
Uganda Community 
School-based 
Household
Community 
Household
Community 
School-based 
Household
Community 
School-based 
Household 
Health center
Community 
School-based 
Household 
Health center
RTI International
Additional 
countries
Haiti School-based 
Distribution 
posts
NA NA School-based 
Distribution 
posts
NA IMA-World 
Health
Sierra Leone Community 
Household
Community 
Household
School-based Community 
School-based 
Household
NA Helen Keller 
International
Bangladesh RTI International
Cameroon Helen Keller 
International
Nepal RTI International
Southern Sudan Malaria 
Consortium
Togo Health and 
Development 
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Program, cumulatively more than 98 million persons over 
three years.) 
  Because a treated person in these integrated programs often 
receives a drug package comprising more than one medication, 
the metric ‘treatments provided’ was developed to record the 
number of individual drug treatments received by the target 
population. As indicated in   Figure 1B  , 222 million drug treat-
ments were provided during the first three years of support to 
the 7 implementing countries by the NTD Control Program. 
The details of these treatments provided (drugs treatments 
distributed by the seven participating national programs) are 
shown in   Table 5  . 
        Quantity/value of drugs delivered.   As the national programs 
supported by NTD Control Program funds increased in number 
and expanded in scope, the number of donated tablets of drug 
delivered to the national NTD programs has also increased. 
  Table 6   shows that in year 3 alone more than 300 million drug 
tablets were donated and delivered to the countries receiving 
NTD Control Program support. The value of these drugs (as 
defined by each specific donation program) exceeded $575 
million dollars in year 3 and has totaled more than $1.4 billion 
dollars in the program’s first three years. 
        Coverage.    The   sine qua non   for success of preventive 
chemotherapy programs is high rates of drug coverage in 
the disease-endemic populations. Although varying among 
countries and for specific programs within each country, 
programmatic coverage (the percentage of targeted persons 
who actually received the drug) was generally good (  Table 7  ). 
These values were based on numbers reported by the drug 
distributors and their supervisors; and when these reported 
values were subjected to validation studies in coverage surveys, 
there was generally good agreement between the reported and 
surveyed coverage values (data not shown). 
      For  successful  elimination  and  large-scale  control  programs 
using the preventive chemotherapy strategy, it is also neces-
sary to have broad geographic coverage (the percentage of 
disease-endemic districts covered by PCT programs).   Figure 2   
records the numbers of districts under treatment of each 
disease during the first 3 years. It shows that for each of the 
NTDs, the geographic coverage increased progressively dur-
ing the three years of NTD Control Program activity. Because 
the program can only expand (i.e., increase geographic cov-
erage) in areas where mapping is complete, those NTDs 
where mapping is more advanced (e.g., onchocerciasis where 
the African Program for Onchocerciasis Control has been 
a strong and consistent source of funding for mapping and 
implementation) have the greatest geographic coverage. By 
the end of year 3, geographic coverage in the 7 implementing 
countries had increased for each of the NTDs, ranging from 
a high of 95% for onchocerciasis to a low of 50% for schisto-
somiasis. The treatment gap remaining for each disease in the 
first seven countries and targeted in the upcoming years can 
be appreciated in   Figure 2  . 
    Training/national  capacity  building.     At the heart of all PCT 
programs is the community that is affected by NTDs. Training 
is designed to empower these communities to treat NTDs 
within their own populations. The NTD Control Program has 
 Table 3 
    Guidelines for disease-specific mapping   
Disease Guideline
Lymphatic filariasis
Indicator Prevalence of   Wuchereria bancrofti  
antigenemia or   Brugia   microfilaremia
Persons tested > 15 years old
Living > 10 years in the community/village
Diagnostic tool Immunochromatograpy (ICT) antigen test of 
finger stick blood or parasitologic 
examination of night blood films
Sample size Up to 300 to identify at least 1 antigen-
positive or microfilaremia-positive person 
(i.e., exceeding threshold of 1%)
Sampling frame At least 1 village/site in an implementation 
unit
Convenience sample or otherwise
Onchocerciasis
Indicator Prevalence of subcutaneous nodules or 
  Onchocerca volvulus   microfilariae in the 
skin
Persons tested 50 adults ≥ 20 years of age and living in the 
village for > 10 years
Diagnostic tool Palpation of subcutaneous nodules 
(also possible:parasitologic examination 
of skin snip)
Sample size 50 per village; 2–4% of villages in focus
Sampling frame Convenience or otherwise
Schistosomiasis
Indicator Questionnaire; prevalence of microhematuria 
or parasite eggs in urine for   Schistosoma 
haematobium 
Prevalence of parasite eggs in stool for 
  S. mansoni 
Persons tested School age children (7–14 years of age)
Diagnostic tool Dipsticks for microhematuria/urine filtration 
for   S. haematobium 
Kato-Katz or sedimentation test for   S. mansoni 
Sample size 50 school age children per school or site
Sampling frame At least 5 villages with expected high 
prevalence in each ecologic zone
In the village: convenience sample
Soil-transmitted helminths
Indicator Prevalence of eggs in stool
Persons tested School age children (7–14 years of age)
Diagnostic tool Kato-Katz
Sample size 50 SAC per school or site
Sampling frame 5 villages with expected high prevalence in 
each ecologic zone
In the village: convenience sample
Trachoma
Indicator Prevalence of trachomatous inflammation 
(TF) and trichiasis (TT)
Persons tested 1–9 year-old children for trachomatous 
inflammation (TF)
> 15 year-old children for TT
Diagnostic tool Clinical examination of eyes
Sample size 50–100 children per cluster
Sampling frame 20 clusters per implementation unit (district 
or other) Probability Proportional to 
Estimated Size
 Table 4 
    Mapping of districts in NTD Control Program countries  *     
    *      Aggregated total number of districts in the first seven implementing countries (iden-
tified in   Table 2  ). NTD = neglected tropical disease; USAID = United States Agency for 
International Development; LF = lymphatic filariasis; STH = soil-transmitted helminths.   
Disease
Baseline before NTD 
Control Program Start
Districts 
Mapped 
with USAID 
Support
Districts 
Mapped 
with Other 
Support
No. remaining 
districts that 
need mapping 
at the end of 
year 3
No. districts 
already 
mapped
No. districts 
needing NTD 
mapping
LF 493 33 8 12 13
Onchocerciasis 379 147 0 143 4
Schistosomiasis 346 180 170 0 10
STH 356 170 170 0 0
Trachoma 423 103 68 24 1110 LINEHAN AND OTHERS
supported the training of more than 220,000 persons during 
its first three years, with most being community-based health 
workers/drug distributors (  Figure 3  ). Working at levels from 
the central ministries to the communities, a cascade of training 
has been facilitated to support social mobilization, community 
outreach, supply chain organization and management, and 
technical implementation of PCT. The fundamental content 
of training courses and refresher training is similar for 
most programs, but local needs dictate local training and 
organizational strategies. 
    NTD  Control  Program  expenditures.    Analysis  of  expen-
ditures during the first three years shows that the program 
fulfilled its mandate that at least 80% of program funds be 
spent on country program implementation. During the first 
three years, the program received $40,728,320 in funding. 
Program expenditures by the end of year 3 were $37.9 
($2.8 million remaining to be spent), with 81.3% expended for 
country program activities and purchase of essential drugs and 
with 18.7% used for overall management of the program (its 
grants, monitoring and evaluation, reporting, documentation 
of best practices, technical and representational meetings, and 
advocacy activities). 
 The breakdown of program expenditures reflects the diverse 
set of activities that must be supported to enable treatment of 
persons at the community level. Of the 81.3% of funds going 
directly for country program activities and supplies (  Figure 4  ), 
the largest portion (28%) was spent on the MDAs themselves, 
including for social mobilization, drug distribution, and per-
sonnel supervision. Almost equal portions (19–22%) went to 
drug procurement, capacity building, and country-led man-
agement and program monitoring. The remaining 11% was 
required for the initial mapping to define disease distribution. 
    Although not yet specifically documented for this program, 
it should be noted that previous costing studies of programs to 
control one or more NTDs have shown that in addition to the 
external support received by disease-endemic countries, the 
national ministries contribute approximately an equal level 
of resources in staff salaries and in-kind resources to achieve 
success.  14  
    DISCUSSION 
  The whole concept of program integration is, undeniably, 
complex and involves, as described by some,  15   not only the 
multiple domains of policy, activity, and organizational struc-
ture, but also multiple levels of integration intensity: coordi-
nation, collaboration, and consolidation. To others, however, 
integration is more an attitude than a formula, a focus on try-
ing always to find ways to carry out multiple activities with 
the most efficient and cost-effective use of available resources. 
From either perspective, the arguments for integrating control 
programs that target the NTDs remain strong: the populations 
affected are much the same, the strategic approach (preven-
tive chemotherapy) is essentially identical, and the drugs for 
implementing programs are largely donated, readily avail-
able, highly safe, and effective. Furthermore, opportunities 
to embed or integrate NTD control activities within school-
health programs and through other platforms of health service 
delivery offer the promise of greater efficiency, long-term sus-
tainability, and national capacity strengthening. 
  Early pilot studies confirmed the general feasibility of suc-
cessful integration of NTD control efforts,  6–  8   but two major 
questions have remained. 1) Can the integrated NTD control 
activities effective in pilot studies be successfully expanded to 
programs at full national scale? 2) Which elements of individ-
ual NTD programs are most successfully integrated and how 
are they best implemented? The findings in this present report 
address the first question, showing clearly that integration of 
multiple disease-specific NTD control programs can be suc-
cessfully implemented at full national scale. Assessment and 
analyses addressing the second question, to define the most 
effective and cost efficient ways of integrating specific pro-
gram activities, are still underway. 
  From the data in   Figure 1  , it is clear that funds from the 
USAID support of the NTD Control Program have been 
effective in facilitating national programs to support, organize, 
implement, and monitor integrated, formerly disease-specific 
programs targeting WHO’s five tool-ready NTDs.  3   In the 
7 study countries receiving support during the program’s first 
 F igure   1 .      A  , Persons reached (dark bars) and treatments pro-
vided (light bars) during each of the first three years of the Neglected 
Tropical Disease (NTD) Control Program.   B  , Cumulative totals of 
persons reached (dark line) and treatments provided (light line) over 
the first three years of the NTD Control Program.       
 Table 5 
  NTD  Control  Program–supported  treatments *   
Drug Year 1 Year 2 Year 3
IVM 12,049,342 15,551,089 43,945,901
DEC 0 0 2,111,826
ALB/MBD 13,263,152 20,221,501 51,906,980
PZQ 2,621,978 8,839,281 10,783,581
AZT/TET 8,881,685 13,417,513 19,106,346
Total 36,816,157 58,029,384 127,854,635
    *     IVM = ivermectin; DEC = diethylcarbamazine; ALB/MBD = albendazole/mebendazole; 
PZQ = praziquantel; AZT/TET = azithromycin/tetracycline.   11 INTEGRATED IMPLEMENTATION OF NTD PROGRAMS
three years, progressive scaling up resulted in an additional 16 
million persons receiving appropriate PCT in the first year, 27 
million in the second year, and 55 million in the third year, for 
a cumulative total of more than 98 million persons reached in 
three years and quite clearly proving the feasibility for inte-
grated NTD programs to be carried out at full national scale. 
 Introduction of this funding also effected a major qualitative 
change in national programs targeting the NTDs. Even though 
in the year prior to the NTD Control Program, up to 33 mil-
lion people had received treatment of NTDs in disease-spe-
cific programs in the target countries, these national programs 
were constantly challenged to identify funds, most often on a 
yearly basis, to support their program activities. With the NTD 
Control Program, a secure funding source was established, so 
that these national programs not only could achieve broader 
disease control in their populations but also could undertake 
proper planning to address their NTD problems more effec-
tively and cost efficiently. 
  Different from single-disease programs where each person 
reached equals one treatment given, in the integrated pro-
grams each person reached receives a drug ‘package’ usually 
containing more than one drug. Therefore, the metric ‘treat-
ments delivered,’ the number of times a single drug dose is 
administered, had to be developed to record this program-
matic achievement. More than 222 million treatments were 
provided by national programs during the first three years of 
the NTD Control Program. It can be predicted with certainty, 
based on recent studies assessing the impact of disease-specific 
NTD programs,  16,  17   that when the program assesses the health 
benefits from these treatments after 3–5 years of treatment, its 
impact on personal, societal, and economic well-being will be 
seen to be enormous. 
  What even these numbers by themselves fail to impart, how-
ever, is an understanding of the magnitude and importance of 
the public-private partnership between specific pharmaceu-
tical companies and the public sector. It has been the dona-
tion of extraordinary amounts of drugs (by GlaxoSmithKline, 
Johnson & Johnson, Merck & Co., Inc., and Pfizer) that has 
made possible the successes of these global efforts to control 
or eliminate the NTDs. In addition, although the drug manu-
facturers have without question provided most of the drugs 
used in this program, the generic drugs needed for schisto-
somiasis and STH control and for LF elimination in coun-
tries outside Africa have also been obtained and provided to 
national programs in the NTD Control Program by a number 
of governmental and nongovernmental partner organizations, 
including the Department for International Development 
(United Kingdom), the United Nations Children’s Fund, 
University of Notre Dame, WHO, the World Food Program, 
and World Vision. 
  In addition to its role in facilitating integrated national 
MDA programs to provide treatments for their at-risk popu-
lations, the NTD Control Program has, of necessity, supported 
countries in mapping the distribution of infection and develop-
ing, in collaboration with WHO, action plans that will enable 
them to begin or expand implementation of drug delivery in 
the coming years. Already the empirical experience gained 
from three years of program activities in the first seven imple-
menting countries has contributed appreciably to the develop-
ment of new guidelines, norms, and regionalized strategies that 
will facilitate and accelerate program activities in the many 
countries still needing to begin their integrated NTD control 
programs. 
  Major challenges still lie ahead for creating integrated pro-
grams targeting NTD control or elimination, not the least of 
which is the large number of countries requiring these pro-
grams. Such a need provides political challenges not just for 
the national governments, which must commit their limited 
resources and energy to the programs, but also for the bilat-
eral donors to support these national commitments, the drug 
manufacturers to sustain their long-term pledges, and the 
various implementing partners necessary to support national 
programs to carry out their integrated NTD implementation 
strategies. 
  In addition to these political challenges, technical challenges 
also remain, the first being definition of the geographic scope of 
each of the NTDs. Mapping the infections must be completed, 
 Table 6 
    Number of tablets of donated drugs provided to national NTD programs in year 3 of the NTD Control Program  *     
Country ALB IVM PZQ DEC Zithromax †  MBD Tetracycline  (tubes) ‡  Total  tablets § 
Burkina Faso 11,862,300 33,913,000 8,553,600 158,642 54,487,542
Ghana 8,753,500 28,633,500 9,724,000 53,280 3,615,000 50,779,280
Haiti 6,933,600 22,300,000 29,233,600
Mali 4,976,900 14,494,500 3,000,000 8,972,640 198,904 31,642,944
Niger 8,465,000 22,128,500 5,498,500 11,509,920 200,000 47,801,920
Sierra Leone 4,500,000 16,716,850 3,000,000 3,797,498 28,014,348
South Sudan 324,500 9,215,000 3,000,000 505,440 2,400 13,047,340
Uganda 13,947,700 30,286,000 5,598,720 7,000,000 56,832,420
Total 59,763,500 155,387,350 24,222,500 22,300,000 35,193,600 14,412,498 559,946 311,839,394 §   
    *     Because donated drugs are provided to the countries in the year prior to their distribution, the number of drugs delivered (e.g., here in year 3) will not equal the number of treatments provided 
in the same year. Of the provided drugs, essentially all are used for treating the NTDs according to the national strategies (indicated in   Table 2  ) and with coverage effectiveness approximated in 
  Table 7  . Any drugs unused in one year are applied to the requirements for treatment in the following year. NTD = neglected tropical disease; ALB = albendazole; IVM = ivermectin; PZQ = prazi-
quantel; DEC = diethylcarbamazine; MBD = mebendazole.   
    †     In addition, 629,616 bottles of pediatric oral suspension (~3 pediatric doses per bottle) were provided.   
    ‡     Tetracycline ointment tubes are used at the rate of 2 tubes per child for a 6-week course of treatment.   
    §     Does not include bottles of Zithromax pediatric oral suspension or tubes of tetracycline ointment.   
 Table 7 
    Programmatic coverage in NTD Control Program countries  *     
NTD Control Program Country Year 1 Year 2 Year 3
Fast-track countries Burkina Faso 82–86 79–97 89–100  † 
Ghana 78–88 71–92
Mali 69–100 †  58–88 85–89
Niger 91–99 73–88 78–93
Uganda 57–97 62–97
Additional countries Haiti 100  † 
Sierra Leone 82–93
    *      Presented as a range across the different drug packages used in each country. 
NTD = neglected tropical disease.   
    †     100% values likely reflect incomplete census counts of the targeted population.   12 LINEHAN AND OTHERS
not just to identify prevalence, but, even more importantly, 
to define exactly what action must be taken at which level of 
prevalence and in which geographic area for each of the NTDs. 
Then, once it is determined what action is required for each of 
the NTDs, the treatment gaps for specific diseases (e.g., schis-
tosomiasis [  Figure 2  ]) must be addressed and the efficiencies 
of integration (in terms of both cost and impact) identified and 
quantified so that cost-efficient integrated programs can be 
established. It does, of course, remain absolutely essential that 
the specific goals of each individual program being integrated 
be met, including those program targets that are not MDA-
dependent, such as morbidity control (surgical and otherwise) 
for LF and trachoma, and the water and sanitation goals of 
the schistosomiasis, STH, and trachoma programs. Sacrificing 
a program’s goals simply for the sake of integration is totally 
inappropriate. Thus, the elimination targets for LF and blind-
ing trachoma by 2020  11,  12   must be kept, and for onchocerciasis 
in the Americas and selected foci in Africa, the elimination 
targets must also be respected.  18,  19  
  In just three years, the NTD Control Program has exceeded 
program expectations that had been based on previous pilot 
program activities. This achievement demonstrates not only 
the feasibility of going to national scale with an integrated 
approach but also that efficiencies can be achieved through 
integration. These efficiencies come, in large part, from remov-
ing duplication in the operations of specialized disease pro-
grams as co-implementation is introduced. They also stem from 
the ability of the NTD programs to implement PCT through 
community networks, schools and existing health service deliv-
ery platforms, such as child health days. Going forward, even 
greater gains may accrue as opportunities are pursued strate-
gically to leverage or complement other development-sector 
efforts, such as water and sanitation improvements, or other 
health-sector inputs, such as malaria control activities. This 
 F igure   2.        Number of districts covered by mass drug administration (MDA) treatment during the first three years of the Neglected Tropical 
Disease (NTD) Control Program in the seven implementing countries (an aggregated total of 526 districts in these countries). For each of the dis-
eases targeted, the bottom bar depicts the number of districts known to be at risk (dark blue bar), the number known not to be at risk (white bar), 
and those where uncertainty remains because of incomplete mapping (light blue bar). For each of the diseases, the top bar represents the number of 
districts implementing MDA with the United States Agency for International Development NTD Control Program support (the red bars indicate 
the number supported in the first year, the orange bar indicates the additional numbers supported in the second year, and the yellow bar indicates 
the additional supported in the third year). For each disease, the middle bar (green) indicates the total number of districts receiving MDA treatment 
supported by any funding source. LF = lymphatic filariasis; Oncho = onchocerciasis; STH = soil-transmitted helminths; Schisto = schistosomiasis.   
*Ghana interrupted transmission of trachoma during year 2 and therefore did not require treatment in year 3.   13 INTEGRATED IMPLEMENTATION OF NTD PROGRAMS
type of integration of NTD control within development efforts 
and on existing health-service delivery platforms holds prom-
ise for even greater program efficiency and its positive impact 
on strengthening national health systems. Although it is clear 
that not all integrated NTD program activities will have such 
health system strengthening effects,  20   it is also clear that many 
of these integrated program activities can very definitely build 
stronger systems for delivering healthcare and disease preven-
tion to these most underserved populations in NTD-endemic 
countries.  21  
  Although the creation of integrated NTD control programs 
has brought with it a wide range of political and technical chal-
lenges whose importance should not be underestimated,  20  there 
can be little question but that today’s increased attentiveness 
and support for NTD control provide important opportuni-
ties to advance the health of the world’s neediest populations 
towards global health equity in ways never before possible. 
This current experience of the USAID NTD Control Program 
has proven already that an integrated approach to these dis-
eases is feasible at full national scale. What still remains now 
is to draw further on the experiences of this young program 
to define those elements of disease-specific program integra-
tion that can yield the greatest benefits cost-effectively and 
cost-efficiently. There appears to be no reason why such inte-
grated NTD programs, following general WHO guidelines and 
the accumulating experience of a growing number of coun-
tries, cannot be replicated in all places where they are needed, 
so long as necessary political commitment and support can be 
maintained. 
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of Health [MOH], orange indicates training for trainers, green indicates training for supervisors, purple indicates training for drug distributers, and 
blue indicates training for others).       
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million expended on country program implementation during the first 
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